Announced Wed, 5 Aug · 17:48 IST
Q1FY27: Revenue falls 23%, PAT turns negative on weak CDMO and NJ Bio losses
Revenue DeclinePat NegativeEbitda Margin CompressionExceptional ItemResults View source PDFExplain this filing
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+4.2%1-day move
₹428.40
prior close
₹417.90
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+2.2+2.1+2.9+6.9+4.2+4.5+8.4+3.8+3.6+4.3————
Up moveDown movePending
AI summary
Cohance Q1FY27 revenue fell 23.1% YoY to Rs 422 crore. Adjusted EBITDA dropped 93% to Rs 9 crore, margins contracting from 24.4% to 2.2%. Adjusted PAT swung to loss of Rs 43 crore from profit of Rs 59 crore. Standalone held up better at 9.2% EBITDA margin. NJ Bio posted Rs 33 crore EBITDA loss. Management expects Q1 as weakest quarter, with improvement from Q2 and YoY growth returning in H2 FY27. AGM set for September 17, 2026.
Likely market impact
Sharp decline on lumpy CDMO demand and NJ Bio losses. Management guides H2 recovery. Sapala reorganization may strengthen nucleic acid business.